The Rotterdam and Prospect studies have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular health outcomes because it more specifically delivers the long-chain menaquinones MK-6, 7, 8 and 9.
As the global leader of the supplemental Vitamin K2 category, NattoPharma is excited to announce it will deliver to the market MenaQ7® Full Spectrum. Thanks to a proprietary technological breakthrough, this new innovation provides the vital menaquinone isomers MK-6, 7, 8 and 9.
“Fermented cheese is the best source of K2 in the Western diet, but it is unrealistic to obtain our daily K2 requirements from cheese, and it is not a practical source from a supply perspective,” says Dr. Hogne Vik, NattoPharma Chief Medical Officer. “To that end, NattoPharma has once again broken the mold and offers to the market a raw material that is reflective of this range of menaquinones.”
This latest advancement offers the market another natural, allergen-free MenaQ7® variety that provides the vital menaquinone isomers MK-6, 7, 8 and 9 for optimal and maximal delivery of vitamin K2 with respect to absorption, half-life and biological activity.
“NattoPharma has once again created a raw material that speaks directly the natural dietary supplement consumer, who is drawn to comprehensive nutritional sources,” says Daniel Rosenbaum, NattoPharma CEO. “We welcome the opportunity to meet with companies at this year’s SupplySide West to officially launch this market-changing innovation.”
MenaQ7® Full Spectrum will be the centerpiece of NattoPharma’s booth (P115) at SupplySide West 2017.